/ Print /

IN THE PIPELINE

Novel therapies could stem burden of diabetic eye diseaseA better understanding of the pathophysiologic mechanisms of diabetes has resulted in improved control of its local and systemic comorbidities. Further developments are needed, however, considering the growing number of diabetic patients and who are at risk for late-stage diabetic eye disease.
ARMOR surveillance study update gives current insights on antibiotic resistance for clinical ocular isolatesThe most recent analyses of data from the ARMOR (Antibiotic Resistance Monitoring in Ocular micRoorganisms) Surveillance Program can guide clinicians choosing antibiotic therapy for initial empiric therapy and infection prophylaxis. The information also reinforces the importance of prudent antibiotic prescribing to limit the development of bacterial resistance to existing options, according to Penny Asbell, MD.
FDA okays biosimilar for several cancers
FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
27-gauge presents new paradigm of intraocular precision for vitrectomyModern 27-gauge equipment for vitrectomy has introduced a new paradigm in vitreoretinal surgery marked by enhanced precision and control.
Temporary scleral buckling offers advantages for retinal detachmentTemporary scleral buckling performed with a removable external device provides the benefits of scleral buckling while addressing its downsides as surgery for a detached retina.
Anatomic outcome more precise in defining DME treatment failureThe goal of treatment for diabetic macular edema is to maintain or improve vision, but improvement of edema is a better metric for determining whether the treatment is having a benefit or failing.
FDA warns Pfizer’s Meridian over EpiPen flawsFDA warned about an injunction or seizure if Meridian Medical Technologies, a division of Pfizer, does not correct its problems with the EpiPen (epinephrine auto-injector).
FDA warns about deaths in cancer drug trials
FDA warns about deaths in cancer drug trialsAn increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.
Reactivating cones possibility in addressing RPGlucose entrapment in the retinal pigment epithelium is responsible for central vision loss in retinitis pigmentosa. Injecting wild-type rods into the eye to restore glucose transportation or injecting glucose into the subretinal space can facilitate cone regeneration.
Blockbuster diabetes drug earns heart indication
Blockbuster diabetes drug earns heart indicationA top-selling diabetes drug has gained a cardiovascular indication from FDA.